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Abstract 
Introduction Early onset breast cancer (occurring under age 40) 
tend to exhibit a different, aggressive phenotype, and are usually 
associated with hereditary BRCA1 or BRCA2 mutations. We in-
vestigated the levels of Hsp27, HER2/Neu, and ER positivity, in 
early onset breast cancer patients. Materials and Methods 
Eighteen paraffin blocks of tissues from patients diagnosed with 
invasive ductal carcinoma of no specific type (IDC-NST) age 
below 39 years (mean 34 years) who underwent surgery or sur-
gical biopsy in Dr. Soetomo General Hospital, Surabaya, in the 
period of January 2014 - December 2014. The control group con-
sisted of 112 patients aged older than 40 who underwent resec-
tion with the same diagnosis within the same period. All speci-
mens were examined for Hsp27 expression, ER status, and 
HER2/Neu amplification. Results The younger patient pool typ-
ically has higher tumor grade and show less Hsp27 expression. 
Sixteen (88.9%) of early-onset patients has grade II or III cancer, 
with 55.55% presenting with grade III cancer. Meanwhile, 79 
(70.53%) of late onset patient has grade II or III cancer, with 
26.78% presenting with grade III cancer. Seventy-seven out of 
112 (68.75%) patients in the older group has positive ER status, 
compared to 8 out of 18 (45.45%) of early-onset patients. All 
within the younger patient pool show Hsp27 score less than the 
median score. HER2/Neu scoring distribution is similar across 
age groups. Statistical analysis using Chi-square and Spearman 
rank correlation test show a statistically significant difference in 
Hsp27 expression between early-onset and late-onset patients, 
but fail to show statistical significance between ER status or 
HER2/Neu score and age. Conclusion Difference in Hsp27 lev-
els show a statistically significant difference between early-onset 
and late-onset breast cancer patients. Meanwhile, estrogen re-
ceptor expression and HER2/Neu amplification failed to show 
statistically significant difference between early-onset and late-
onset patients. 
Key words: early onset breast cancer, breast cancer, Hsp27, 
HER2/Neu, estrogen receptor 
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Introduction 
Breast cancer is the most common 
cancer among women and remains one of 
the most common cause of death. Accord-
ing to WHO GLOBOCAN Breast Cancer 
Factsheet 20121, breast cancer is the most 
common cancer in the world, with an esti-
mated 40.2 cases per 100.000 people (36% 
of all cancers), and has the second highest 
mortality rate among all cancers.  
Breast cancer is extremely uncom-
mon below the age of 20, where benign 
breast lesions are much more common2; but 
its occurrence increases according to age 
and at the age of 90, about 20% of women 
will have had breast cancer. Because the in-
cidence of early-onset breast cancer is low, 
and the risk is calculated to be increased up 
to 100-fold after menopause, breast cancer 
is thought to be very heavily influenced by 
hormonal factors. Age at menarche and 
menopause is also important as it deter-
mines the time frame of the patient’s expo-
sure towards carcinogenic hormones.3 
Breast cancer is further histopatho-
logically divided into several types. The 
first is invasive ductal carcinoma with no 
specific type (NST), which has no speficic 
differentiating feature2. This classification 
is an exclusion-based diagnosis, and the 
most common type of breast cancer. The 
second type is intraductal carcinoma, which 
is a potentially invasive precancer lesion in 
the breast, where abnormal cells are found 
to line one or more of the breast ducts. In-
vasive lobular carcinoma comprises 5-10% 
of all breast cancers.4 Another method of 
classification is by the TNM method, which 
stages cancers based on its primary tumor 
size, nodal and distant metastasis. Accord-
ing to its receptor status, breast cancers can 
express endocrine receptors (estrogen and 
progesterone), HER2 receptor, all of these 
or none of these. This classification will de-
termine the chemotherapy and endocrine 
therapy regime.  
About 75% of all breast cancers are 
ER-Positive, which means the tumor re-
sponds the presence of estrogen, and 65%of 
these are also PR-Positive, which means it 
also responds to progesterone.5 ER has 
proved to be a very successful therapeutic 
target for ER+ cancers, as proved by anti-
estrogenic drugs such as tamoxifen and ra-
loxifen. ER+ cancers is also correlated with 
better histological differentiation and has a 
better prognosis.6 
About 20-25% of all breast cancers 
make an excess of a protein called 
HER2/Neu, and these cancers have the ten-
dency to be more aggressive and rapidly 
growing. The drug Trastuzumab/Herceptin 
has dramatically reduced the risk of recur-
rence in such cases.7 About 10-17% of all 
breast cancers are triple-negative, showing 
none of the receptors mentioned above. 
These cancers tend to be bigger in size and 
most are high-grade NST invasive ductal 
carcinoma.8 The lack of any specific thera-
peutic target makes the prognosis for these 
cancers worse, with the lowest point within 
the first 3-5 years.9 
Heat shock protein 27 (Hsp27) is a 
small molecular weight heat-shock protein 
that acts as a chaperone for protein folding 
induced by heat or other stress.10 Induction 
of this protein by estrogen holds a signifi-
cant role in the pathogenesis of breast can-
cers. The ability of estrogen to induce 
Hsp27 was proven in a study by Porter et 
al.11 which showed that the addition of 12-
beta-estradiol to MCF-7 breast cancer cell 
line doubled the levels of Hsp27 mRNA. 
Hsp27 is also thought to function as an anti-
apoptotic agent, interacting with both the 
mitochondrial-dependent and independent 
pathways of apoptosis. Due to this function, 
Hsp27 is thought to play a large role in re-
sistance towards several chemotherapeutic 
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drugs such as gemcitabine and doxorubi-
cin.12 
Hsp27 also has the capacity to reg-
ulate cell adhesion and migration. Several 
studies show the activity of Hsp27 in in-
creasing  metastatic potential of tumor cells 
in rats and increase resistance towards ther-
apy.13 This role in cell migration is im-
portant, because the last step of tumor de-
velopment involve tumor invasion to sur-
rounding tissues and dissemination into 
metastatic colonies in distant organs.14 The 
increase of Hsp27 in tumor cells may be 
caused by several genes such as p53 loss-
of-function or by protooncogenes such as 
HER and c-Myc.15 Overexpression of 
Hsp27 has been associated with shorter dis-
ease-free survival. 
Theoretically, we know that Hsp27 
is a downstream target of estrogen receptor 
signalling and plays a role in cancer cell di-
vision, which lends to the theory that the ex-
pression of Hsp27 and estrogen receptor 
should be correlated. 11 However, the con-
nection between Hsp27 and estrogen recep-
tor expression as analysed by prior studies 
seem to be ambiguous. Several studies, 
such as those by Hayes and Thor, Love and 
King, Straume et al. and Ciocca and 
Calderwood16-19 indicated the presence of a 
positive correlation between Hsp27 expres-
sion and estrogen receptor positivity. On 
the other hand, several other studies such as 
those by Asfour et al.20 and Seymour, Bez-
woda and Meyer21 did not find any signifi-
cant correlation between Hsp27 score and 
estrogen receptor status. Also, samples an-
alysed in studies that show significant pos-
itive correlation often include those who are 
already undergoing various forms of ther-
apy, effects from which may befuddle the 
results. 
While breast cancer treatment has 
rapidly evolved over the decades with in-
creased use of adjuvant therapies, mortality 
from breast cancer in early-onset patients 
has not decreased in the last 36 years.22 Tu-
mors in younger patients tend to be more 
advanced and less curable, and often have 
familial factors that pose them to be less re-
sponsive to therapy, such as BRCA1 or 
BRCA2 mutations. BRCA-mutated tumors 
tend to have higher grade and less respon-
sivity to hormone therapy than tumors diag-
nosed in older women.23 Young breast can-
cer patients often present with larger tumor 
and have metastatic lymph nodes or vascu-
lar invasion, and therefore do not follow the 
trends of breast cancer treatment in general. 
In this study, we seek to elucidate how hor-
monal receptors and HER2/Neu expression 
intersect with the age of presenting patients, 
which may provide insight as to why early-
onset breast cancer has worse prognosis.
 
Materials and Methods 
This study is an analytical observa-
tion study designed as a single-sampling 
cross sectional study. The study samples 
are paraffin blocks from patients diagnosed 
with invasive ductal carcinoma of no spe-
cific type (IDC-NST) regardless of grade or 
stage, aged 39 years old or younger (mean: 
34 years) who underwent surgery or surgi-
cal biopsy in Dr. Soetomo General Hospi-
tal, Surabaya, within the period of January 
2014-December 2014. The control group 
consisted of 112 patients diagnosed with 
IDC-NST aged 40 or older who underwent 
resection within the same period; all speci-
men in the control group is tested for ER 
and HER2/Neu status. The exclusion crite-
ria are patients who already underwent 
other forms of therapy, such as preoperative 
chemotherapy or radiotherapy. All samples 
were treated with immunohistochemistry 
by staff from Anatomic Pathology Depart-
ment of Dr. Soetomo General Hospital. Re-
sults are cross-tabulated and analyzed with 
Chi-square test. Furthermore, Spearman 
ranked correlation test was performed to 
discover whether there is any statistically 
significant correlation between the varia-
bles.  
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Results 
Early-onset breast cancer, defined 
as those occurring at or below the age of 39, 
occurs in a total of 18 (13.84%) of all pa-
tients that satisfy the inclusion criteria. The 
most prominent age range overall is 51-60 
years (53.84%) with total mean age of 
54.03 years old. Within the early-onset 
group, the mean age is 34.1 years old. The 
youngest participant is 26 years old and the 
oldest is 74 years old. Within the early on-
set group, 8 samples (44.44%) show posi-
tive estrogen receptor status whereas 67 
samples (58.03%) in the late-onset group 
show positive estrogen receptor status (Ta-
ble 1). 
All patients under the age of 30, and 
more than half (53.33%) of those aged 31-
40, present with Stage III cancer upon ad-
mission. A total of 15 (77.78%) of early-on-
set patients present with Stage III or IV can-
cer, while 79 (70.53%) of late onset patients 
present with stage III or IV cancer. Stage IV 
cancer is most prominent in those aged 60 
or above (30.8%). Sixteen (88.9%) of early-
onset patients has grade II or III cancer, 
with 55.55% presenting with grade III can-
cer. Meanwhile, 79 (70.53%) of late onset 
patient has grade II or III cancer, with 
26.78% presenting with grade III cancer. 
Grade III cancer is most prominent in the 
younger than 30 (66.7%) and 31-40 years 
old (40%) age group (Table 2). 
Cross tabulation between patients’ 
age and estrogen receptor positivity seemed 
to show higher propensity for negative ex-
pression in the younger population (Figure 
1). In patients with positive ER status, 77 of 
85 (90.58%) is aged 40 or older. 77 out of 
112 (68.75%) patients aged 50 or older has 
positive estrogen receptor status. Mean-
while, in the early-onset group, 10 out of 18 
(55.55%) patients have negative estrogen 
receptor status. Two (66.66%) patients in 
the below 30 age group has negative estro-
gen receptor status, while 8 (53.55%) pa-
tients in the 30-40 age group has negative 
estrogen receptor status. In all age groups 
above 40 years old, 62.5%, 75.7% and 
53.8% showing positive ER status in the 
40-50 years old, 50-60 years old and >60 
years old groups, respectively (Table 3). 
Table 1.  Data of the characteristics of the research 
subjects 
Category Range Amount 
Age (years) 
<30 3 (2.3%) 
31-40 15 (11.5%) 
41-50 16 (12.3%) 
51-60 70 (53.8%) 
>60 26 (20%) 
Estrogen receptor 
status 
Positive 85 (65.4%) 
Negative 45 (34.6%) 
Hsp27 expression 
0-3 
 
17(13.2%) 
4-6 47 (36.1%) 
7-9 48 (36.9%) 
10-13 18 (13.8%) 
HER2/Neu 
expression 
Negative 26 (20%) 
+1 18 (13.8%) 
+2 26 (20%) 
+3 60 (46.2%) 
Hsp27, heat shock protein 27; HER2/neu 
Cross tabulation between age and 
HER2/Neu status show that each age group 
mostly has similar distributions of 
HER2/Neu intensity, with a total of 46.15% 
of patients staining strongly positive for 
HER2/Neu expression (Figure 2). One-
fifths of all patients show no HER2/Neu ex-
pression. This distribution mostly holds for 
every age group except for the age group 
below 30 years old, where one patient 
(33.3%) showed weak HER2/Neu staining 
intensity and two patients stained strongly 
positive (66.6%) for HER2/Neu expression. 
The oldest age group which included pa-
tients above 60 years old showed the least 
amount of HER2/Neu negative samples, 
with only 15.4% of samples rendering neg-
ative staining (Table 4). 
Cross tabulation between age and 
Hsp27 score shows that all patients aged 50 
years and below has Hsp27 score that is less 
than the median score, suggesting that 
 52 
J Asian Med Stud Assoc 
Original Papers 
Table 2.  Cross tabulation between age and grade/stage at presentation 
Stage 
Age 
Total 
<30 31-40 41-50 51-60 >60 
I 0 1 (6.7%) 0 4 (5.7%) 2 (7.6%) 7 (5.4%) 
II 0 3 (20%) 4 (25%) 15 (21.4%) 8 (30.8%) 30 (23.1%) 
III 3 (100%) 8 (53.3%) 8 (50%) 34 (48.6%) 8 (30.8%) 61 (46.9%) 
IV 0 3 (20%) 4 (25%) 17 (24.3%) 8 (30.8%) 32 (24.6%) 
Grade 
Age 
Total 
<30 31-40 41-50 51-60 >60 
I 0 2 (13.3%) 4 (25%) 21 (30%) 8 (30.8%) 35 (26.9%) 
II 1 (33.3%) 7 (46.7%) 7 (43.75%) 33 (47.14%) 9 (34.6%) 57 (43.8%) 
III 2 (66.7%) 6 (40%) 5 (31.25%) 16 (22.86%) 9 (34.6%) 38 (29.2%) 
 
Table 3.  Cross tabulation between age and estrogen receptor status 
ER status 
Age 
Total 
<30 31-40 41-50 51-60 >60 
Positive 1 (33.3%) 7 (46.7%) 10 (62.5%) 53 (75.7%) 14 (53.8%) 85 (65.4%) 
Negative 2 (66.7%) 8 (53.3%) 6 (37.5%) 17 (24.3%) 12 (46.2%) 45 (34.6%) 
Total 3 15 16 70 26 130 (100%) 
ER, estrogen receptor 
 
Table 4. Cross tabulation between age and HER2/Neu status 
HER2/Neu 
score 
Age 
Total 
<30 31-40 41-50 51-60 >60 
- 0 4 (26.7%) 4 (25%) 14 (20%) 4 (15.4%) 26 (20%) 
+ 1 (33.3%) 2 (13.3%) 2 (12.5%) 8 (11.4%) 6 (23.1%) 18 (13.84%) 
++ 0 3 (20%) 3 (18.7%) 16 (22.9%) 4 (15.4%) 
26 (20%) 
 
+++ 2 (66.6%) 6 (40%) 7 (43.8%) 32 (45.7%) 12 (46.1%) 60 (46.15%) 
Total 3 15 16 70 26 130 (100%) 
 
Table 5. Cross tabulation between age and Hsp27 score 
Hsp27 score 
Age 
Total 
<30 31-40 41-50 51-60 >60 
0-3 2 (66.6%) 9 (60%) 0 (0%) 6 (8.6%) 0 (0%) 17 (13.1%) 
4-6 1 (33.3%) 6 (40%) 14 (87.5%) 26 (37.1%) 0 (0%) 47 (36.1%) 
7-9 0 (0%) 0 (0%) 2 (12.5%) 33 (47.1%) 13 (50%) 48 (36.9%) 
10-13 0 (0%) 0 (0%) 0 (0%) 5 (7.1%) 13 (50%) 18 (13.8%) 
Total 3 15 16 70 26 130 (100%) 
Hsp27, heat shock protein 27 
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younger patients tend to show less Hsp27 
expression (Figure 3). In patients aged 50 
or above, 64 out of 96 (66.66%) samples 
exceed the median score. Eleven out of 17 
(64.7%) samples with little to no Hsp27 ex-
pression belong to the early-onset age 
group (Table 5). 
 
Figure 1. Bar chart illustrating HER2/Neu expres-
sion as related to patient age 
 
Figure 2. Bar chart illustrating estrogen receptor 
expression as related to patient age 
Chi-square tests were performed 
correlating Hsp27 score, ER expression and 
HER2/Neu expression, with the signifi-
cance threshold set at 0.05. Results for 
HER2/Neu (N=130, p=0.944) and estrogen 
receptor expression fail to show a statisti-
cally significant correlation. Chi-square re-
sults for Hsp27 (N=130, p=<0.001) on the 
other hand show a strong correlation with 
patients’ age. Similarly, Spearman ranked 
correlation test showed a statistically sig-
nificant correlation between Hsp27 expres-
sion and patients’ age (p=<0.001), but 
failed to show any significant correlation 
between age and HER2/Neu expression 
(p=0.183) or estrogen receptor expression 
(p=0.281). 
 
Figure 3. Bar chart illustrating Hsp27 expression 
as related to age 
 
Discussion 
While being relatively rare, early-
onset breast cancer show different trends 
compared to breast cancer in general, often 
presenting with more advanced tumor stage 
and grade, and being less responsive to 
chemotherapy or adjuvant treatment.22,23 
Early-onset breast cancer is also influenced 
by familial factors such as BRCA1 or 
BRCA2 mutations, and therefore it is 
thought to be chemically distinct from 
breast cancers in general.24 Study by 
Sundquist et al. indicates that the type of 
breast cancer associated with lower mortal-
ity in older age groups may be a less aggres-
sive disease than the breast cancer develop-
ing in younger women.22 Early-onset breast 
cancer is also shown to be less responsive 
to hormonal and adjuvant therapy16 which 
renders a population study elucidating the 
relation between age and hormonal receptor 
or HER2/Neu status relevant. 
 54 
J Asian Med Stud Assoc 
Original Papers 
This study samples 130 breast can-
cer patients undergoing treatment in Dr. 
Soetomo General Hospital, January-De-
cember 2014, including 18 early-onset pa-
tients aged younger than 40 from various 
grades and stages of cancer with archived 
paraffin block specimens of their tumors. 
All samples are primary tumors and chosen 
patients are those were never exposed to 
chemotherapy, hormonal therapy, or immu-
notherapy. These specimens are processed 
with immunohistochemistry and stag-
ing/grading at presentation, hormonal re-
ceptor expression, HER2/Neu amplifica-
tion and Hsp27 intensity is cross tabulated 
with data on the patient’s age.9,15 
Cross tabulation between patients’ 
age and grade/stage upon presentation seem 
to confirm the hypothesis that early-onset 
tumors tend to have more advanced grade 
than their late-onset counterparts, with 
88.89% early-onset patients presenting 
with grade II or III tumors, compared to the 
70.53 in late-onset patients. The data on 
staging seem to be equally distributed 
across all age groups, although we also take 
into account that most patients tend to pre-
sent at later stages in the Indonesian soci-
ety. While existing literature seems to indi-
cate that older patients tend to have positive 
ER status, while younger patients tend to be 
ER-negative, Chi-square and Spearman 
rank correlation test performed on our sam-
ples fail to show a statistically significant 
correlation. This opens up new avenues on 
investigation regarding ER receptor expres-
sion in the Indonesian population – as of 
now, there is still a lack of data regarding 
this issue, especially on the prevalence of 
BRCA1/BRCA2 mutations the Indonesian 
population, which is connected to early-on-
set cancer and lack of hormone receptor ex-
pression.25  
Cross tabulation between age and 
HER2/Neu status also show that each age 
group mostly has similar distributions of 
HER2/Neu intensity, with a total of 46.15% 
of patients staining strongly positive for 
HER2/Neu expression and one-fifths of all 
patients show no HER2/Neu expression. 
This distribution mostly holds for every age 
group except for the age group below 30 
years old. Statistical analysis confirms this 
result, with both Chi-square and Spearman 
correlation test failing to show any statisti-
cally significant difference. 
 On the other hand, age and Hsp27 
shows significant correlation in our sam-
ples. Cross-tabulation between age and 
Hsp27 score shows that all patients aged 50 
years and below has Hsp27 score that’s less 
than the median score, suggesting that 
younger patients tend to show less Hsp27 
expression, while in patients aged 50 or 
above 66.66% of samples exceed the me-
dian score. Both Chi-square (p = < 0.001) 
and Spearman ranked correlation test (p = < 
0.001) confirms the presence of a strong 
correlation between Hsp27 and age. Hsp27 
is a protein that plays a role in apoptosis and 
metastasis and has been correlated with re-
sistance towards certain chemotherapeutic 
drugs. This may be one explanation as to 
why early-onset cancers tend to be more ag-
gressive and show a worse prognosis 10 
 
Conclusion 
We conclude that early-onset breast 
cancer does have a connection to more ad-
vanced grade and lack of Hsp27 expression. 
However, our study failed to show statisti-
cally significant correlation between age 
and estrogen receptor or HER2/Neu expres-
sion. This shows possible differences in im-
munohistochemical properties than be-
tween early-onset breast cancer and other 
breast cancers, which could influence fu-
ture therapeutic approach. Further study is 
needed to possibly connect these data to 
BRCA1/BRCA2 mutations, or by perform-
ing further patient follow-up or larger mul-
ticentre studies.
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